Millendo Therapeutics (NASDAQ:MLND) Earns “Buy” Rating from Jefferies Financial Group

Jefferies Financial Group reaffirmed their buy rating on shares of Millendo Therapeutics (NASDAQ:MLND) in a research note released on Monday, BenzingaRatingsTable reports. They currently have a $22.00 price target on the stock. Jefferies Financial Group also issued estimates for Millendo Therapeutics’ Q3 2019 earnings at ($0.80) EPS, Q4 2019 earnings at ($0.81) EPS, FY2019 earnings at ($3.11) EPS, FY2020 earnings at ($2.65) EPS, FY2021 earnings at ($2.71) EPS, FY2022 earnings at ($2.18) EPS and FY2023 earnings at ($0.64) EPS.

A number of other equities analysts have also recently issued reports on MLND. ValuEngine upgraded shares of Millendo Therapeutics from a hold rating to a buy rating in a research note on Thursday, August 1st. CIBC began coverage on shares of Millendo Therapeutics in a research note on Tuesday, July 16th. They issued an outperform rating and a $26.00 price target on the stock. Wedbush reiterated a buy rating and issued a $24.00 price target on shares of Millendo Therapeutics in a research note on Thursday, August 15th. Citigroup began coverage on shares of Millendo Therapeutics in a research note on Monday, July 15th. They issued an outperform rating and a $26.00 price target on the stock. Finally, Zacks Investment Research cut shares of Millendo Therapeutics from a buy rating to a hold rating in a research note on Saturday, August 17th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $22.97.

Shares of Millendo Therapeutics stock opened at $7.00 on Monday. The stock has a market cap of $93.73 million, a price-to-earnings ratio of -0.40 and a beta of 2.62. The firm’s 50-day moving average is $6.92 and its 200 day moving average is $12.25. Millendo Therapeutics has a 1 year low of $4.56 and a 1 year high of $17.34. The company has a debt-to-equity ratio of 0.04, a current ratio of 5.90 and a quick ratio of 5.90.

Millendo Therapeutics (NASDAQ:MLND) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.07. On average, equities analysts expect that Millendo Therapeutics will post -3.21 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of MLND. BlackRock Inc. lifted its stake in Millendo Therapeutics by 1,738.4% during the 2nd quarter. BlackRock Inc. now owns 468,342 shares of the company’s stock valued at $5,414,000 after acquiring an additional 442,866 shares during the period. Vanguard Group Inc. lifted its stake in Millendo Therapeutics by 62.2% during the 2nd quarter. Vanguard Group Inc. now owns 331,285 shares of the company’s stock valued at $3,829,000 after acquiring an additional 126,994 shares during the period. International Biotechnology Trust PLC lifted its stake in Millendo Therapeutics by 187.5% during the 2nd quarter. International Biotechnology Trust PLC now owns 177,825 shares of the company’s stock valued at $2,056,000 after acquiring an additional 115,965 shares during the period. Renaissance Technologies LLC lifted its stake in Millendo Therapeutics by 100.3% during the 2nd quarter. Renaissance Technologies LLC now owns 208,864 shares of the company’s stock valued at $2,414,000 after acquiring an additional 104,567 shares during the period. Finally, AWM Investment Company Inc. lifted its stake in Millendo Therapeutics by 288.1% during the 2nd quarter. AWM Investment Company Inc. now owns 77,629 shares of the company’s stock valued at $897,000 after acquiring an additional 57,629 shares during the period. Institutional investors and hedge funds own 50.47% of the company’s stock.

About Millendo Therapeutics

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Read More: What is the CBOE Russell 2000® Volatility Index?

Analyst Recommendations for Millendo Therapeutics (NASDAQ:MLND)

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.